The Titration Ladder, As Written on the Label

The short version

Tirzepatide is given as a once-weekly injection under the skin (subcutaneous). The FDA label specifies a starting dose of 2.5 mg once weekly for four weeks — a dose that is intentionally too low to produce much effect on blood sugar or weight, but gentle enough for the body to adjust without severe nausea. After that, the dose steps up in 2.5 mg increments every four weeks at minimum, through strengths of 5, 7.5, 10, 12.5, and 15 mg. The three maintenance doses used in the large SURPASS and SURMOUNT trials are 5, 10, and 15 mg; the 7.5 and 12.5 mg strengths are titration rungs, not intended long-term targets. Slow titration is the primary tool for managing the GI side effects (nausea, constipation, diarrhea) that are most common during dose increases. The drug stays in the body roughly five days — the elimination half-life — which is why once-weekly dosing maintains steady blood levels. The dose schedule and all interaction notes described on this page are summaries of the FDA-approved label, not recommendations from this site.

The label-defined dose schedule

The FDA-approved labeling for tirzepatide specifies six dose strengths, all administered as a subcutaneous injection once weekly: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg ^[17].

The 2.5 mg dose is an initiation dose only. The label is explicit that 2.5 mg is not intended for glycemic or weight-loss efficacy — it exists to introduce the body to the drug at a tolerable starting point so that gastrointestinal side effects are minimized while the dose is escalated upward ^[17].

After the four-week initiation period at 2.5 mg, the dose can be increased in 2.5 mg increments, with a minimum interval of four weeks between dose steps. The four-week minimum is not arbitrary — it corresponds to the approximate time needed to reach steady state after a dose change, given the ~120-hour (5-day) elimination half-life and an accumulation ratio of about 1.6 ^{[12] [17]}.

Maintenance dose options listed on the label depend on indication. For type 2 diabetes, maintenance options are 5 mg, 10 mg, or 15 mg once weekly. For chronic weight management, maintenance options are also 5 mg, 10 mg, or 15 mg. The 7.5 mg and 12.5 mg strengths are titration steps between maintenance options, not stable long-term targets ^[17].

Why the titration is slow

The titration speed is the primary lever clinicians use to manage gastrointestinal tolerability. In the pooled SURMOUNT-1 through SURMOUNT-4 safety analysis, nausea was reported in 24-33% of participants, diarrhea in 17-23%, constipation in 11-17%, and vomiting in 6-13%, with the rate of each event tracking dose ^[15]. These events were predominantly mild to moderate, concentrated during the dose-escalation phase, and generally resolved with continued dosing.

Discontinuation rates for adverse events across the SURMOUNT program were generally below 8% ^[15]. The pattern means that slower titration — for example, holding at a dose step for longer than the minimum four weeks if a participant is still adjusting — is the standard clinical approach to managing tolerability. The label allows this: four weeks is a minimum step interval, not a maximum.

In SURPASS-4, comparing tirzepatide to titrated insulin glargine in adults with T2DM and elevated cardiovascular risk, hypoglycemia rates were lower with tirzepatide than with insulin glargine ^[3]. This is because the insulin secretion stimulated by tirzepatide is glucose-dependent: the drug amplifies insulin release when blood glucose is elevated and stops amplifying it when blood glucose returns to normal — a mechanism that intrinsically limits hypoglycemia risk in patients not also on insulin or sulfonylureas.

Route, sites, and the missed-dose rule

Tirzepatide is administered as a subcutaneous injection — into the fatty tissue just beneath the skin, at the abdomen, the thigh, or the upper arm. Injection sites are rotated. This is the only approved route of administration ^[17].

The drug is supplied in pre-filled single-dose pens or vials, refrigerated at 2-8°C, with limited room-temperature storage allowed per the manufacturer's labeling.

The missed-dose rule on the label is precise: if a dose is missed and the next scheduled dose is more than 96 hours (4 days) away, the missed dose can be taken as soon as possible. If less than 4 days remain until the next scheduled dose, the missed dose is skipped and the regular weekly schedule resumes ^[17]. That rule follows directly from the pharmacokinetics — at a 5-day half-life, dosing closer than 4 days apart would produce overlapping peaks rather than the steady weekly cycle the drug was designed for.

The pharmacokinetics that justify weekly dosing

A population pharmacokinetic analysis pooled across phase 1 through phase 3 studies established the following profile for subcutaneous tirzepatide ^[12]:

• Elimination half-life: approximately 120 hours (~5 days)
• Plasma protein (albumin) binding: approximately 99%
• Absolute bioavailability after subcutaneous injection: approximately 80%
• Tmax (time to peak plasma concentration): 8 to 72 hours after injection
• Steady state: reached after approximately 4 weeks of weekly dosing
• Accumulation ratio: approximately 1.6
• Volume of distribution: approximately 10.3 L
• Clearance: approximately 0.061 L/hour

Tirzepatide is metabolized through proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid tail, and amide hydrolysis. It is not metabolized through the cytochrome P450 system, which means clinically relevant CYP-mediated drug interactions are not expected. Metabolites are excreted in urine and feces; minimal unchanged drug is recovered ^[12].

Special populations and clinically important interactions

Pharmacokinetic studies have not identified a need for dose adjustment based on renal or hepatic impairment. The labeling still calls for caution in patients with severe gastroparesis or a history of pancreatitis ^[17].

Tirzepatide is not recommended in pregnancy, and women of reproductive potential are advised to use contraception during treatment. The label specifically notes that tirzepatide may reduce the efficacy of oral contraceptives through delayed gastric emptying, particularly during initiation and after each dose escalation. The label recommends switching to a non-oral contraceptive or adding a barrier method for 4 weeks after initiation and 4 weeks after each dose escalation ^[17].

The labeled contraindications are a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and a known serious hypersensitivity reaction to tirzepatide or any of its excipients ^[17].

None of the dose numbers, intervals, or interaction notes above are recommendations from this site. They are summaries of what is written on the FDA-approved labeling ^[17]. Actual prescribing, titration choices, and dose adjustments for any individual person are decisions made by a licensed clinician who knows that person's medical history.